Case Study of Intrahepatic Combined Immunochemotherapy after Hepatic Resection for Four Patients with Liver Metastases from Colorectal Cancer

Abstract

We performed intrahepatic combined immunochemotherapy (ACIT) after hepatic resection for patients with liver metastases from colorectal cancer to prevent recurrence in the liver. ACIT consists of 5 different agents, ie, recombinant interleukin-2 (IL-2), OK-432, adriamycin, cyclophosphamide and famotidine. The survival rate of patients with ACIT (40-month survival rate; 100%) was higher than that of 9 patients without intrahepatic therapy (40-month survival rate; 45%). Natural killer activity was augmented significantly after ACIT. Thus, intrahepatic combined immunochemotherapy after hepatic resection for liver metastases from colorectal cancer may be worth performing in further clinical trial.